Skip to main content

Table 1 Input table for the COVID-19 epidemiological characteristics, mask mandate, and vaccinate-or-test requirement

From: Estimated public health impact of concurrent mask mandate and vaccinate-or-test requirement in Illinois, October to December 2021

Study Period (Dates covered)

Oct. 20 – Dec. 20, 2021

Assumed COVID-19 Epidemiological Characteristics

 Latent period durationa

2 days

 Basic reproduction numberb

R0 = 5

 % cases asymptomaticc

40%

 Infectiousness of asymptomatic casesd

75%

 % vaccinated in general populatione

53.8%

 Vaccine effectivenessf

88%

 Immunity durationg

180 days

Inputs Specific to COVID-19 Mask Mandate

  Mask effectivenessh

   Pre-mandate

3.6% – 16.8%

   Post-mandate

6.1% – 21.3%

Inputs Specific to COVID-19 Vaccinate-or-Test Requirement

 Size of the population affected by requirementi

929,370

% vaccinated in sub-population affected by requirementj

 Pre-requirement

64.8%

 Post-requirement

75.9%

  1. aPer the literature, we used a two-day latent period associated with the SARS-CoV-2 Delta variant [20, 21]
  2. bPer the literature, we used a basic reproduction number of R0 = 5.0 associated with the SARS-CoV-2 Delta variant [22, 23]. The infectivity distribution varies over time and is spread over an 11-day period [24, 25], and the effective reproduction number further depends on the estimated impact of non-pharmaceutical interventions (NPIs) and the size of the susceptible population, see Technical Appendix for more details
  3. cAsymptomatic COVID-19 cases. Patients can be infected, and become infectious, without being symptomatic. They can and likely do contribute to onward transmission of the pathogen [26]
  4. dInfectiousness of asymptomatic COVID-19 cases relative to symptomatic cases [26]
  5. eBased on CDC COVID-19 vaccination data [27]—these data represent overall coverage among all ages at the beginning of the study period
  6. fCOVID-19 vaccine effectiveness is based on the effectiveness of two doses of the monovalent mRNA BNT162b2 (Pfizer-BioNTech, Comirnaty) against the Delta variant [28]
  7. gWe assume SARS-CoV-2 immunity lasts 180 days on average [29], this includes both vaccine-induced and disease-induced immunity
  8. hMask effectiveness is the product of (i) mask efficacy and (ii) mask compliance. The resultant values are the average mask effectiveness in the state of Illinois, for the time-period studied. See Technical Appendix for more details
  9. iBased on Data from the U.S. Bureau of Labor Statistics [30]. See Appendix Table A2
  10. jBased on data from the Centers for Disease Control and Prevention (CDC)’s National Healthcare Safety Network (NHSN) for CMS-certified nursing homes in IL [31]. Note that this data only represents a sub-population of the total population affected by the vaccinate-or-test requirement. See Appendix Table A3
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us